{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:13:04Z","timestamp":1769731984732,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009002","name":"Ministry of Education Science Culture and Sports of the Republic of Armenia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111260","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T19:59:51Z","timestamp":1700769591000},"page":"111260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Intranasal immunotherapy with M2 macrophage soluble factors in post-COVID hyposmia: A pilot study"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8997-3586","authenticated-orcid":false,"given":"E.Ya","family":"Shevela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.N.","family":"Davydova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.V.","family":"Meledina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.S.","family":"Bogachev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Ostanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.A.","family":"Kozlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.R.","family":"Chernykh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.111260_b0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamaoto.2020.1379","article-title":"Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19","volume":"146","author":"Boscolo-Rizzo","year":"2020","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.intimp.2023.111260_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2022.103607","article-title":"Recovery from Covid-19 smell loss: Two-years of follow up","volume":"43","author":"McWilliams","year":"2022","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.intimp.2023.111260_b0015","doi-asserted-by":"crossref","first-page":"eabf8396","DOI":"10.1126\/scitranslmed.abf8396","article-title":"COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters","volume":"13","author":"de Melo","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2023.111260_b0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19","volume":"24","author":"Meinhardt","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.intimp.2023.111260_b0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/diseases11020079","article-title":"Post-COVID-19 anosmia and therapies: stay tuned for new drugs to sniff out","volume":"11","author":"Riccardi","year":"2023","journal-title":"Diseases"},{"key":"10.1016\/j.intimp.2023.111260_b0030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.expneurol.2007.06.009","article-title":"Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury","volume":"209","author":"Donnelly","year":"2008","journal-title":"Exp. Neurol."},{"issue":"12","key":"10.1016\/j.intimp.2023.111260_b0035","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2147\/IDR.S208576","article-title":"Functional aspects, phenotypic heterogeneity, and tissue immune response of macrophages in infectious diseases","volume":"22","author":"de Sousa","year":"2019","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.intimp.2023.111260_b0040","first-page":"e000080.01","article-title":"The generation and properties of human M2-like macrophages: potential candidates for CNS repair?","volume":"2","author":"Chernykh","year":"2010","journal-title":"Cell. Ther. Transplant."},{"key":"10.1016\/j.intimp.2023.111260_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/sji.12401","article-title":"The phenotypic and functional features of human M2 macrophages generated under low serum conditions","volume":"83","author":"Sakhno","year":"2016","journal-title":"Scand. J. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2023.111260_b0050","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.3727\/096368914X684925","article-title":"Clinical experience with autologous M2-macrophages in children with severe cerebral palsy","volume":"23","author":"Chernykh","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.intimp.2023.111260_b0055","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3727\/096368915X690279","article-title":"Safety and therapeutic potential of M2-macrophages in stroke treatment","volume":"25","author":"Chernykh","year":"2016","journal-title":"Cell Transplant."},{"key":"10.1016\/j.intimp.2023.111260_b0060","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/pathogens10060698","article-title":"Short-term efficacy and safety of oral and nasal corticosteroids in COVID-19 patients with olfactory dysfunction: A European multicenter study","volume":"10","author":"Saussez","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.intimp.2023.111260_b0065","first-page":"1483","article-title":"Topical administration of mometasone is not helpful in post-COVID-19 olfactory dysfunction","volume":"12","author":"Hintschich","year":"2022","journal-title":"Life (basel)"},{"key":"10.1016\/j.intimp.2023.111260_b0070","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00405-022-07665-4","article-title":"Effectiveness of olfactory training in COVID-19 patients with olfactory dysfunction: A prospective study","volume":"280","author":"Lechien","year":"2023","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"10.1016\/j.intimp.2023.111260_b0075","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/00034894221111093","article-title":"Tailored approach for persistent olfactory dysfunction after SARS-CoV-2 infection: A pilot study","volume":"132","author":"de Sousa","year":"2023","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.intimp.2023.111260_b0080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/alr.23116","article-title":"Use of platelet-rich plasma for COVID-19 related olfactory loss, a randomized controlled trial","volume":"13","author":"Yan","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.intimp.2023.111260_b0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00001756-199310000-00010","article-title":"Macrophage-enhanced neurite regeneration of adult dorsal root ganglia neurones in culture","volume":"5","author":"Hikawa","year":"1993","journal-title":"Neuroreport"},{"key":"10.1016\/j.intimp.2023.111260_b0090","unstructured":"E.Y. Shevela, L.V. Sakhno, M.Y. Kafanova, M.N. Davydova, M.M. Andrushkevich, A.A. Ostanin, E.R. Chernykh, A method for obtaining a conditioned medium with a regenerative potential for intranasal administration in the treatment of diseases of the central nervous system, RF Patent 2637407, filed 06\/01\/2016, and issued 04.12.2017."},{"key":"10.1016\/j.intimp.2023.111260_b0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.26599\/JNR.2019.9040010","article-title":"Intranasal delivery of M2 macrophage-derived soluble products reduces neuropsychological deficit in patients with cerebrovascular disease: a Pilot Study","volume":"7","author":"Shevela","year":"2019","journal-title":"J. Neurorestoratol."},{"key":"10.1016\/j.intimp.2023.111260_b0100","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00405-020-05965-1","article-title":"Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study","volume":"277","author":"Lechien","year":"2020","journal-title":"Eur. Arch. Otorhinolaryngol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923015874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923015874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:15:29Z","timestamp":1761588929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923015874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":20,"alternative-id":["S1567576923015874"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111260","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal immunotherapy with M2 macrophage soluble factors in post-COVID hyposmia: A pilot study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111260"}}